<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04522999</url>
  </required_header>
  <id_info>
    <org_study_id>CSP007</org_study_id>
    <nct_id>NCT04522999</nct_id>
  </id_info>
  <brief_title>Study of Photobiomodulation Effect on Electroretinogram Outcomes in Dry Age-Related Macular Degeneration</brief_title>
  <acronym>ELECTROLIGHT</acronym>
  <official_title>An Objective Study to Evaluate the Ability of Photobiomodulation to Improve Electroretinogram Outcomes in Subjects With Dry Age-Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiThera, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiThera, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the ability of Photobiomodulation (PBM) treatment using the Valeda® Light&#xD;
      Delivery System to improve Electroretinogram (ERG) outcomes in subjects with dry Age-related&#xD;
      Macular Degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open label, prospective pilot study to evaluate retinal function after PBM&#xD;
      treatment in eyes with dry AMD using ERG. The target enrollment is 15 subjects in up to two&#xD;
      sites in the US. All subjects will receive PBM Treatment.&#xD;
&#xD;
      Subjects will receive three PBM treatments per week for three weeks for a total of nine&#xD;
      sessions over 3 weeks.&#xD;
&#xD;
      The primary analysis will examine multi-focal ERG function changes from baseline to Month 1.&#xD;
      Secondary analyses will examine multi-focal ERG function change from baseline to Month 3 and&#xD;
      6. Other endpoints will include other functions of ERG, ETDRS Visual Acuity, Contrast&#xD;
      Sensitivity, Perimetry, Color Vision test and the Amsler grid test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Actual">August 13, 2021</completion_date>
  <primary_completion_date type="Actual">August 13, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ERG function</measure>
    <time_frame>3 months</time_frame>
    <description>ERG assessments (Multifocal ERG (mfERG), Photopic Negative Response (PhNR), Multi-luminance Flicker ERG (ML-FERG) and Fixed-luminance Flicker ERG (FL-FERG)) will provide an output of retinal function.</description>
  </primary_outcome>
  <other_outcome>
    <measure>ETDRS Visual Acuity</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of Visual function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mars Contrast Sensitivity</measure>
    <time_frame>3 months</time_frame>
    <description>Measurement of Visual function.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Photobiomodulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valeda™ Light Delivery System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Photobiomodulation</intervention_name>
    <description>The Valeda™ Light Delivery System</description>
    <arm_group_label>Photobiomodulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 50 years of age at Screening visit&#xD;
&#xD;
          -  ETDRS BCVA letter score of between 50* and 75* (Snellen equivalent of 20/100 to 20/32)&#xD;
&#xD;
          -  Diagnosis of dry AMD&#xD;
&#xD;
          -  Able to communicate well with the Investigator and able to understand and comply with&#xD;
             the requirements of the study&#xD;
&#xD;
          -  Informed of the nature of this study and has provided written, informed consent in&#xD;
             accordance with institutional, local and national regulatory guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of neovascular maculopathy&#xD;
&#xD;
          -  Presence of center involving GA within the central ETDRS 1 mm diameter at Screening&#xD;
&#xD;
          -  Media opacities, including cataracts, which might interfere with visual acuity or&#xD;
             imaging in the study eye(s)&#xD;
&#xD;
          -  Posterior capsule opacification, which might interfere with visual acuity or imaging&#xD;
             in the study eye(s)&#xD;
&#xD;
          -  Invasive eye surgery (e.g. cataract, capsulotomy) on a qualifying eye within three 3&#xD;
             months prior to Screening&#xD;
&#xD;
          -  Visually significant disease in any ocular structure apart from dry AMD&#xD;
&#xD;
          -  Serious medical illness that will prevent the subject from performing study activities&#xD;
&#xD;
          -  Presence of or history of malignancy within the past 5 years&#xD;
&#xD;
          -  Presence or history of known light sensitivity to yellow light, red light, or near&#xD;
             infrared radiation (NIR), or if they have a history of light activated CNS disorders&#xD;
             (e.g. epilepsy, migraine)&#xD;
&#xD;
          -  History of neurologic condition known to affect visual function&#xD;
&#xD;
          -  History of drug, alcohol or substance abuse within 3 months prior to Screening&#xD;
&#xD;
          -  Participation in any other clinical study at time of screening, or has received an&#xD;
             investigational drug or treatment with an investigational device within 3 months prior&#xD;
             to Screening&#xD;
&#xD;
          -  In the opinion of the Investigator, is unlikely to comply with the study protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Perich Eye Center</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

